Statins use and its impact in EGFR-TKIs resistance to prolong the survival of lung cancer patients: A Cancer Registry Cohort Study in Taiwan

Lung Cancer

Nguyen PA, et al. Cancer Sci 2020.


Statins have shown beneficial treatment as chemotherapy and target-therapy for lung cancer. This study aims to investigate the effectiveness of statins in combination with epidermal growth factor receptor- tyrosine kinase inhibitors (EGFR-TKIs) therapy on resistance and mortality of lung cancer patients. A population-based cohort study was conducted using the Taiwan Cancer Registry database. From January 1, 2007, to December 31, 2012, a total of 792 non-statins and 41 statins users had undergone

EGFR-TKIs treatment and were included in this study. All patients were monitored until the event of death or were changed to another therapy. Kaplan-Meier estimators and Cox proportional-hazards regression models were used to computing overall survival. We found that the mortality was significantly lower with statins compared to non-statins group (4-year cumulative mortality, 77.3%; 95% CI, 36.6%-81.4% vs. 85.5%; 95% CI, 78.5%-98%; p=0.004). Also, statin use was associated with a reduced risk of death in the group that had a tumor size<3 cm (HR, 0.51, 95% CI, 0.29-0.89) and in the group with CCI-scores<3 (HR, 0.6; 95% CI, 0.41-0.88; p=0.009). In our study, statins are associated with prolonged survival time in lung cancers with EGFR-TKIs and play a synergistic anticancer role.